‹ Iovance Biotherapeutics
Ch 4 · An Interim CEO at the Inflection
Chapter 4 · Management
Interim CEO, permanent search.
Frederick Vogt holds the seat. Iovance is hunting for a permanent CEO at exactly the moment commercial execution matters most.
↓ scroll to read
✦ The bottom line
Iovance is currently being run by an interim CEO — Frederick Vogt, Ph.D., J.D., a longtime Iovance executive. The 10-K confirms the company is actively recruiting a new permanent CEO. That uncertainty sits at the top of the org chart while the launch is in full swing.
↓ the brief below
The leadership arc
2014
Iovance goes public; spends years on lifileucel development for advanced melanoma.
Feb 2024
Amtagvi receives FDA approval — first one-time T-cell therapy for a solid tumor.
Aug 2024
Acquires Proleukin (IL-2) from Clinigen, securing supply of a critical drug used alongside Amtagvi.
2025
Prior CEO departs; Vogt named interim CEO. Operating losses widen as launch scales.
Now
Manufacturing centralized at iCTC. Multiple registrational trials underway. CEO search ongoing.
The org · headcount
975
FTEs
975 employees at year-end 2025 — 775 in R&D and commercial manufacturing, 200 in G&A. The mix tilts heavily toward making and shipping Amtagvi.
Source · 10-K · Item 1 — Human Capital Resources · FY2025 · Filed Feb 24, 2026
From the 10-K · the candid CEO disclosure
We continue to recruit a new Chief Executive Officer. However, competition for qualified employees among companies in the biotechnology and biopharmaceutical industry is intense, and no assurance can be given that we will be able [to] attract, hire, retain, and motivate [the right talent].
↳ Iovance is telling you, in its own 10-K, that filling the top job is not yet done and not guaranteed. For a company in launch mode, that's a real risk to acknowledge.
Source · 10-K · Item 1A — Risk Factors (Human Capital) · FY2025 · Filed Feb 24, 2026
⚠
Watch
An experienced interim leader holding the chair — but a CEO transition at the launch inflection is a real risk.
You just finished
Chapter 4 · MANAGEMENT
An Interim CEO at the Inflection
you now read: skin in the game
Up next
Then
Chapter 6 · RISK
The One-Product Risk